Consumer health giant Kenvue delivered higher quarterly earnings and revenue, providing early validation for management's restructuring and brand reinvestment initiatives.

Intensifying shareholder activism and tightening capital markets are placing corporate chief executives on an unprecedented collision course with investors.

Heightened regulatory scrutiny and aggressive shareholder activism are driving public boards to prioritize truly independent, specialized directors.

Bayer has gained regulatory clearance in China for its novel stroke-prevention medication, capturing a global first-in-class approval as it rebuilds its cardiovascular pipeline.